Cardiol Therapeutics Inc - CRDL Net earnings per share for the last four quarters

Official company branding of Cardiol Therapeutics (CRDL)

This daily price chart for Cardiol Therapeutics (CRDL) reflects earnings per share, which currently stands at 19.40. The business relies on external laboratories and contract manufacturing rather than owning its own facilities. Delivery of cardiology treatments is managed through strictly controlled climate chains. The Canadian jurisdiction and the humanitarian profile of the drugs ensure asset stability, completely eliminating geopolitical risks and sanctions pressure.

cardiolrx.com (CRDL): Earnings per share for the last twelve months from 02/11/2024 to 11/17/2026

Financial and market metric breakdowns for Cardiol (CRDL)

- share price and consensus valuation forecast:
Fundamental company valuation:Cardiol Therapeutics Inc CRDL
Product sample of Cardiol Therapeutics Inc

Cardiol Therapeutics' specialization in the therapy of chronic cardiac pathologies creates a foundation for long-term demand for anti-inflammatory drugs. By analyzing the current EPS TTM YoY growth rate, an investor assesses the annual net income per share dynamics, which allows for the identification of the business's real operational efficiency and determines whether profit growth is sustainable or the result of temporary market overheating.